Abstract Body

Long-lasting, latently-infected resting CD4+ T cells are the greatest obstacle to curing HIV infection, as these cells can persist despite decades of treatment with antiretroviral therapy. One approach towards a cure is to reactivate HIV from its latent state, thus promoting virus mediated killing and/or facilitating immune recognition and clearance of infected cells. Interventions that successfully reverse latency, when combined with strategies to enhance the antiviral immune response, may result in a reduction in the size of the persistent HIV reservoir. This presentation will review promising latency reversal approaches that take into consideration the immunologic aspects of virus persistence. Emerging results from in vivo studies in humanized mice and nonhuman primates will be discussed. The immunologic and virologic effects of the selected latency reversal agents will be highlighted.